Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$464.92 USD
-12.98 (-2.72%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $464.91 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRTX 464.92 -12.98(-2.72%)
Will VRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
Other News for VRTX
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Vertex treatment of myotonic dystrophy type 1 granted FDA orphan designation
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug